Biotech News and Comments
At the 51st American Society Hematology (ASH) Annual Meeting in New Orleans, LA. Sunesis presented positive data from two Phase 2 clinical trials of its drug Voreloxin drug for acute myeloid leukemia.
The high-risk biotech firms are proving time after time that they are low risk. Now, following the melting of the economy story, the biotech firms can be seen as no risk compared to the firms that were considered surefire. .
In November, Array hinted to a partnership, but unfortunately, many preferred to listen to the wrong voices. Fortunately, though, there is something called profit-taking.
08 Dec 2009
We are optimistic. The truth is that we are in the process of regaining our enthusiasm for Geron.
The FDA has approved NeurogesX' drug Qutenza (capsaicin patch) for neuropathic pain due to post-herpetic neuralgia (PHN).
Cytokinetics (CYTK) has two programs. Both programs deal with life-threatening conditions that have yet to find satisfactory treatments. T
Could XOMA 052 drug be the key that opens the door to treating several chronic progressive debilitating diseases? If the answer would be yes, it is, then the potential for this product candidate will be enormous.
Is there any reason for ONXX decline?
Using Cytory's Celution® 800 system in an operative procedure enabled fat stem cells and regenerative cells to correct stress urinary incontinence.
